Home >

The Second Round Of The Opening Of The State Procurement With Quantity Will Start Soon.

2020/1/14 11:53:00 0

StateQuantityBid OpeningNormalizationAcceleration

In January 17th, the second round of nationwide procurement will be opened in Shanghai. On the eve of the opening of the bid, on January 9th, the Standing Committee of the Political Bureau of the CPC Central Committee and vice premier of the State Council were holding a symposium at the National Health Insurance Bureau. From the spirit of the conference, the government will vigorously promote the procurement of state procurement and promote the normalization of centralized procurement.

According to people's daily news, the future national collection plan will be formulated by the State Council, and the national health insurance agency will carry out specific implementation. The goal is to take the first more than 160 varieties of the hospital purchase amount from high to low as the focus of future collection, and plan for three years and then make 5-6 batches.

In January 13th, Wang Ying, head of Beijing's Management Consulting Co., Ltd., told reporters in twenty-first Century economic report that the state procurement is an inevitable trend. "Before the national negotiation, a lot of research and evidence collection has been done to determine the price acceptable to the enterprises, and the bargaining price can maintain normal profits on the premise of the amount of the guarantee. We estimate that the production industry enterprises participating in the national centralized production will be about 7% to 9% of the normal profits.

Wang Ying said frankly, this profit is very cruel for enterprises. Enterprises can only choose to adapt. If they can not change, they can only seek acquisitions or direct transformation. "The pharmaceutical industry is a very traditional industry, and its changes are often relatively slow. But since 2016, especially in the past two years, the relevant policies of the country have not changed, but require the industry to change. Regression value will be the direction for the future development of the industry.

The second round of collection is about to open.

In December 29, 2019, the national organization for centralized procurement and use of pharmaceuticals joint procurement office issued the "national drug centralized procurement document". The second batch of state organizations centralized procurement and use of pharmaceuticals was officially launched. The total quantity of 33 drugs purchased and 50 product regulations involved will be opened in Shanghai in January 17, 2020.

These 33 varieties cover diabetes, hypertension, anti-tumor and rare diseases and other treatment areas, involving more than 100 pharmaceutical manufacturing enterprises. Including the last round of amoxicillin, azithromycin and so on, there are acarbose, glimepiride, Ambrisentan tablets and other large variety of drugs.

At the end of 2018, the first batch of "4+7" drug procurement was launched, and pilot projects were carried out in 4+7 cities such as Beijing, Tianjin and Guangzhou. The average price reduction of the 25 winning drugs was 52%. Since September 2019, the successful bidder has expanded its capacity from 11 pilot cities to the whole country, and the average price of the 25 winning drugs has dropped by 25% on the basis of the original price cut.

Unlike in the past, the number of shortlisted enterprises has been greatly increased. It is no longer limited to 3 enterprises. If the declared enterprises are equal to or exceed 9, the number of enterprises entering the list will reach 6.

"Compared with the" 4+7 "pilot and the last round of national collection, the price reduction is even more intense. For the first time, the highest effective bid was set up for the first time, the highest price was set for the quoted price of the enterprise, although the highest effective declaration price was not promulgated clearly, but it was basically not higher than the lowest price in the current market. A head of the marketing department who participated in the second round of bidding for state procurement, said to the twenty-first Century economic report, the competition will be more intense and the price may be even more severe. But for the successful bidder, it can directly cross the previous high threshold of "entering the hospital", and the state has a large amount of protection.

According to the regulations, the total number of enterprises selected for the first 1 years in the country is 50%, and the total number of enterprises selected in the whole country is 2, which can be divided into 60% of the first year's purchasing volume. The actual number of enterprises selected in China is 3, the purchase volume is 70% in the first year, and the total number of purchasing enterprises in the first year is 80%.

Normalization of procurement with quantity

When the procurement of the second wheel volume is about to open, the state has released a strong policy direction, that is, the trend of normalization of procurement with quantity.

On January 9th, vice premier of the State Council, Han, was holding a symposium at the National Health Insurance Bureau. He pointed out that we should vigorously promote the reform of centralized procurement and use of drugs by state organizations, break down all kinds of interests and barriers, promote normalization of concentration and procurement, expand the scope of purchasing varieties, and drive the reform of "three medical linkage".

As early as October 2019, the relevant responsible persons of the State Health Insurance Bureau disclosed that the procurement work with quantity will be carried out normalization, not only in the state, but also in the local area; not only should we make a uniform appraisal of the varieties, but we should also engage in the non evaluation. Not only can many products be purchased with quantity, but the exclusive products can still be purchased with quantity, not only in the field of pharmaceuticals, but also in the field of high value consumables and low value consumables.

It is understood that there are already several provinces are following up with the volume of procurement policy. Just a few days ago, in January 10th, according to the Hunan provincial public resources trading center, in January, Hunan's special centralized procurement of antibacterial drugs entered the tender segment. The quotation and decryption were divided into three rounds, January 11th's simulated quotation, January 13th's first round offer and January 15th's second round quotation. On the same day, the website also issued a notice on the announcement of the results of the special drug procurement Review Group on the announcement of the Hunan provincial special drug procurement, and a total of 1145 products were finally confirmed and qualified.

Wang Ying said national gathering is an inevitable trend. "The state and local governments will have a set of policies to ensure that this matter, such as entering the national health insurance negotiations, is directly entered into the directory of bidding and tendering networks, excluding the proportion of drugs and the amount of safeguards. This amount is now guaranteed by the national reputation, and from last year's 4+7 situation, there is no problem at all."

For example, in January 6th, the Zhejiang medical insurance bureau and the Zhejiang health and Health Committee jointly issued a circular calling for the hospital to eliminate the practice of purchasing the same generic name and stopping the supply of non selected medicines in order to guarantee the agreed purchase volume.

The circular indicated that all medical institutions must also ensure that the drugs that are not selected for the purpose of rational use of drugs should be given priority while ensuring that the drugs are selected for entering the hospital. Hospitals around the country must plan to purchase and use selected and non selected medicines, so as to avoid the extreme situation of supplying only selected drugs or non selected medicines. Efforts should be made to monitor procurement and usage.

Big variety market structure or change

According to people's daily, in January 10th, the National Conference on health care was held in Beijing. The conference summarized the medical security work in 2019, and studied and deployed the key tasks of medical insurance in 2020.

In 2020, the "Medicare medication management measures" will be promulgated to pave the way for future dynamic adjustment of medical insurance directory. The future medical insurance directory adjustment will become a regular, regular and regular fine tuning.

In the future, the national assembly plan will be formulated by the State Council, and the national health insurance agency will carry out the specific implementation. The goal is to take the first more than 160 varieties of the hospital purchase amount from high to low as the focus of future collection, and plan for three years and then make 5-6 batches. Considering that at least 25 varieties are guaranteed for each batch, for the generic drugs that pass the consistency evaluation and at least three or more of each breed will automatically start the national gathering. Other unqualified varieties will be organized by local buyers.

"The state negotiated what species to choose, and the state has also considered it. Prior to the national negotiations, a large number of research and evidence collection have been conducted to determine the prices acceptable to enterprises. We estimate that the production industry enterprises participating in the national centralized production will be about 7% to 9% of the normal profits. Pharmaceutical companies can't survive without making money, but can't make money as easily as they used to. " Wang Ying pointed out to the twenty-first Century economic news reporter.

Wang Ying said that the future big variety is the key target of state and local volume purchase, and the price issue is really cruel for enterprises. "But for the industry, the situation is very fierce. Therefore, if enterprises want to enter health insurance, they can only accept the rules of medical insurance, accept the price, regulate the transformation, optimize the channels, strictly control the quality and production costs."

In January 9th, the price of Wuhan's insulin belt was launched, and the negotiators "negotiate with the lowest price of the state", and the business dropped from only a few cents to the end. In the industry's view, behind the brutal price cuts is a change of over 20 billion yuan under the guidance of the policy.

The above market leader said that the price of the second wheel size will soon be the lowest. According to the highest effective bid and the first year purchase quantity, the total purchase scale corresponds to the total amount of 8 billion 800 million yuan, of which the largest purchase of acarbose is 2 billion 664 million yuan.

Acarbose has just entered the national health insurance directory in 2019 through negotiations on drug prices. Acarbose original research enterprise for Bayer, through the generic drug consistency evaluation of domestic pharmaceutical enterprises only Huadong medicine and green leaf pharmaceutical two. Annual report data show that East China Pharmaceutical acarbose sales revenue in 2015 exceeded 1 billion yuan, sales revenue in 2016 exceeded 1 billion 500 million yuan, in 2017 exceeded 2 billion yuan.

While entering into the national health insurance price negotiation, acarbose will enter a new round of state procurement pilot varieties, or will face greater pressure on price reduction.

Shi Lichen believes that under the impact of the policy, the pharmaceutical industry will undergo tremendous changes. It is estimated that 30% enterprises need to transform. This industry will accelerate the elimination of enterprises in the next 3-5 years.

 

  • Related reading

2020 PTA Market Trend: Smooth Expansion Of Capacity, Lack Of Upward Momentum.

Expert commentary
|
2020/1/14 11:46:00
0

Hebei Dongguang: Many Enterprises Have Already Had A Holiday Cotton Price "Empty Rise"

Expert commentary
|
2020/1/13 17:25:00
1

China Light Textile City: The Annual Turnover Of Clothing In The Lunar New Year Is Decreasing Sharply.

Expert commentary
|
2020/1/13 10:32:00
0

Xinjiang: Bullish Sentiment Is Rising, Cotton Prices Continue To Rise

Expert commentary
|
2020/1/13 10:32:00
0

Ji Lu Yu: Spring Festival Holiday Is Coming Soon, The Textile Market Is Totally Deserted (2020.1.6-10).

Expert commentary
|
2020/1/13 10:07:00
0
Read the next article

The "New Normal" Of The Bond Market Urgently Needs To Improve The Disposal Mechanism Of Default Bonds.

In fact, the frequent occurrence of credit default is a "new normal" in the current bond market. It is also a prominent challenge facing the bond market at present. Coping with challenges